Biotechnology

Celcuity

Geode Capital Increases Stake in Celcuity by 8.4% to $82.9M as Insiders Sell

Celcuity Launches $400 Million Senior Convertible Notes Offering to Repay Loans and Fund Working Capital

Celcuity: gedatolisib combination shows superior Phase 3 results in PIK3CA breast cancer, plans supplemental NDA submission to FDA

Celcuity Expands Breast Cancer Phase III Trial and Files Patent Despite Losses, High Revenue Expected

Celcuity released FY2026 Q1 earnings on May 14 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.9702 (forecast USD -1.0636)

Celcuity Inc. Expands Gedatolisib Phase III Trial and Receives FDA Priority Review Designation

Celcuity to Release FY2026 Q1 Earnings on May 14 After-Market EST, Forecast EPS USD -1.0636

Celcuity director Richard E. Buller sells 9,000 shares of company stock

Celcuity announces significant phase III trial results and plans to submit supplemental NDA

Celcuity Announces Positive Results for Breast Cancer Treatment Trial

Celcuity's stock price rises but volume drops, quarterly EPS beats expectations

Celcuity Announces Expanded Net Loss for 2025 Fiscal Year in Earnings Report

Celcuity released FY2025 earnings on March 25 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -3.79 (forecast USD -3.7245)

Celcuity released FY2025 Q4 earnings on March 25 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.9701 (forecast USD -1.042)

Celcuity to Release FY2025 Q4 Earnings on March 25 After-Market EST, Forecast EPS -1.042 USD

Celcuity Inc's Drug Gedatolisib Receives FDA New Drug Application Acceptance

Wells Fargo Upgrades Celcuity to Outperform with $126 Price Target

Celcuity Inc. Announces Positive Phase 3 Clinical Trial Results for Gedatolisib in Breast Cancer

Celcuity Inc. Director Sells Common Stock

Celcuity Announces Results of Phase III Trial for Gedatolisib

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

CELC

Celcuity raised $575 million via 0.25% convertible senior notes due 2032, netting $557 million. Proceeds were used to retire a $137.5 million term loan facility, reducing financing costs. The notes are convertible at ~$124.53 per share. Management expects the refinancing to support clinical and commercial initiatives.

TradingView

Jefferies Financial

JPMorgan Chase

Toronto Dominion Bank

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Celcuity Raises $575 Million in 0.25% Convertible Notes Due 2032; Net Proceeds $557 Million

Geode Capital Management LLC increased its stake in Celcuity, Inc. (NASDAQ:CELC) by 8.4% in Q4, acquiring 64,213 shares to hold 830,684 shares valued at approximately $82.9 million. Other institutional investors, including EverSource Wealth Advisors and Tower Research Capital, also expanded their positions. Meanwhile, insiders David Dalvey and Richard Buller sold shares under Rule 10b5-1 plans. Analyst sentiment remains mixed, with HC Wainwright maintaining a Buy rating despite cutting EPS estimates, while Wells Fargo lowered its price target.

Market Beat

US Bancorp

BNP Paribas

Wells Fargo

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Geode Capital Management LLC Purchases 64,213 Shares of Celcuity, Inc. $CELC

HC Wainwright lowered its Q3 2026 EPS estimate for Celcuity (NASDAQ:CELC) to ($1.17) from ($1.16), maintaining a 'Buy' rating with a $145 target price. Despite the downgrade, other analysts like Stifel, Guggenheim, and Macquarie maintain positive outlooks with targets ranging from $150 to $160. Institutional investors including Vanguard increased stakes, while insiders Richard Buller and David Dalvey sold shares in May.

Stifel Financial

Citizens Financial

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

HC Wainwright Has Negative Estimate for Celcuity Q3 Earnings

KZIA

Maxim Group analyst Naz Rahman reiterated a Buy rating on Kazia Therapeutics (KZIA), raising the 12-month price target to $30. The upgrade reflects strengthened confidence in Kazia's PI3K/AKT/mTOR strategy, supported by Celcuity's positive Phase 3 results and de-risked mechanisms. Additionally, H.C. Wainwright maintained a Buy rating with an $18 price target.

Tip Ranks

Kazia Therapeutics

Kazia Therapeutics Ltd

Analyst Raises Kazia’s Price Target to $30 and Reiterates Buy on Strengthened Confidence in PI3K/AKT/mTOR Strategy

Celcuity Inc. announced the pricing of an upsized public offering of $500 million in 0.250% Convertible Senior Notes due 2032, increased from the initial $400 million. The notes carry a conversion premium of approximately 40% and mature in August 2032. Net proceeds are estimated at $484.3 million, intended to repay Oxford Finance obligations and fund working capital and general corporate purposes.

GlobeNewswire

Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032

Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032 | CELC Stock News

StockTitan

Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032 | CELC Stock News

Celcuity(CELC.US)

Celcuity Raises $575 Million in 0.25% Convertible Notes Due 2032; Net Proceeds $557 Million

Geode Capital Management LLC Purchases 64,213 Shares of Celcuity, Inc. $CELC

HC Wainwright Has Negative Estimate for Celcuity Q3 Earnings

Analyst Raises Kazia’s Price Target to $30 and Reiterates Buy on Strengthened Confidence in PI3K/AKT/mTOR Strategy

Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032

Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032 | CELC Stock News